Ionis Pharmaceuticals, Inc.

The U.S. Food and Drug Administration accepted our New Drug Application for the treatment of familial chylomicronemia syndrome (#FCS) and granted Priority Review. In addition, enrollment completed in the Phase 3 severe hypertriglyceridemia (#sHTG) clinical program.    Read more: https://lnkd.in/epHKFCF3

At Ionis, we stand firm in our commitment to steward an inclusive and supportive environment where everyone can thrive. We embrace the authenticity, diversity and unique perspectives of our LGBTQ+ colleagues - during Pride month and throughout the year. By championing these values, we strengthen our teams, drive innovation and build a stronger, more compassionate organization for all. #HappyPride (Video taken June 4th at our flag raising on our Carlsbad campus and followed by a Pride celebration lunch with activities organized by our LGBTQIA+ ERG.)

Today, we announced an expanded license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE).   Read more about this announcement and what it means for people living with this serious #RareDisease: https://lnkd.in/en24U9EJ

#GlobalFattyLiverDay, led by Global Liver Institute, is an annual moment in time to educate about fatty liver disease, which impacts over 115 million people globally. #FattyLiverDisease may lead to serious complications like cirrhosis, liver cancer or the need for a liver transplant. Due to the lack of obvious symptoms, people impacted by this condition may struggle to receive a diagnosis. Join us in raising awareness of this progressive condition. 

ICYMI: We presented new Phase 3 data for our investigational medicine for the treatment of hereditary angioedema (#HAE) during a late-breaking session at the 2024 European Academy of Allergy and Clinical Immunology - EAACI Congress, which was simultaneously published in The New England Journal of Medicine. HAE is a rare and life-threatening genetic condition that involves recurrent attacks of severe swelling in various parts of the body, which can cause severe pain and significantly disrupt daily life.    We’re committed to advancing research to better understand how to improve the lives of people living with this #RareDisease, which affects about 20,000 people across the U.S. and Europe. #EAACIcongress 

We’re proud to share The New England Journal of Medicine, part of NEJM Group, today published the positive Phase 3 OASIS-HAE results for our investigational medicine for the treatment of hereditary angioedema (#HAE), which were simultaneously presented in a late-breaking session at #EAACIcongress.     Read the full article to learn more about these exciting results: https://lnkd.in/e9Sb76UZ

Hereditary angioedema (#HAE) is a genetic #RareDisease characterized by frequent and severe swelling attacks that impacts the lives of about 20,000 people across Europe and the U.S. We’re presenting new data from our OASIS clinical program as part of a late-breaking session at the 2024 European Academy of Allergy and Clinical Immunology - EAACI Congress. Learn more about the significance of these results: https://lnkd.in/eCFRdAGH #EAACIcongress 

HCPs: Severely high triglycerides can lead to dangerous consequences. The threat of life-threating acute pancreatitis is ever-present for your patients with severe hypertriglyceridemia (#sHTG) and a genetic form, familial chylomicronemia syndrome (#FCS). Better understand how to diagnose FCS and manage both of these debilitating diseases, including information on dietary restrictions, medications and monitoring procedures: https://tgaware.com/

Asian Pacific Islander Desi American (APIDA) Heritage Month is a time to honor the APIDA communities’ experiences, histories and cultures. We kicked off celebrations with our second annual employee-contributed art exhibit hosted by our DEI Advocates ERG. All Ions connected to the APIDA community were invited to share their art and culture at the event. Scroll through to see and hear more from our Ions.

We look forward to sharing new Phase 3 NEURO-TTRansform subgroup data for our medicine for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (#hATTR-PN) in adults, at the 2024 International Symposium on Amyloidosis (ISA).    Read more about this data: https://lnkd.in/egJz7afu